Hematology/Oncology

Kim YJ, Merle P, Finn RS, Kudo M, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Cho SB, Hsu CH, Huang[...]

Cheon J, Ryoo BY, Chon HJ, Kim HD, Ryu MH, Kim KP, Kang B, Finn RS, Chan SL, Yoo C. Multicenter Phase 2 Trial of[...]

Hargreaves E, Collinson R, Jenks AD, Staszewski A, Tsalikis A, Bodoque R, Arias-Garcia M, Abdi Y, Al-Malki A, Yuan Y, Natrajan R, Haider S, Iskratsch[...]

Pontolillo L, Davis AA, Gerratana L, Medford AJ, Wang J, Nicolo' E, Clifton K, Velimirovic M, Warrior S, Podany E, Andreopoulou E, Serafini MS, Munoz-Arcos[...]

Kudo M, Ren Z, Finn RS, Llovet JM; LEAP-012 investigators. Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply.[...]

Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J,[...]

Kim S, Song M, Williams D, Du W, Cho I, Bae E, Kim J, Goswami A, Shin KH, Park NH, Kim RH. Early cellular events[...]

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the[...]

Jain A, Li VW, Salem J, Reddy ST, Palaskas NJ, Meriwether D. A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular[...]

Meyer T, Finn RS, Borad M, Mahipal A, Edeline J, Houot R, Hausner PF, Hollebecque A, Goyal L, Frigault M, Jeffry Evans TR, Wong KM,[...]